CXCR4 and precursor B-cell acute lymphoblastic leukemia: In the preclinical setting, CXCR4 inhibitors (such as plerixafor/AMD3100 or BKT140 and their derivatives) and genetic inhibition have been used as therapeutic agents to inhibit stroma-induced B-ALL cell growth/metabolism and overcome stroma-mediated drug resistance, and also, consistently with our results, to inhibit disease progression in mouse models of B-ALL59,60.